Our Pipeline
ONO is investigating additional molecules across our four focus areas in clinical trials around the world.
![Lab technician](/sites/default/files/2024-07/Pipeline_Hero.webp)
Combination with nivolumab
Mechanism
Disease Area
Country
Licensor
Development Phase
ONO-4059 (tirabrutinib)
BTK inhibitor
ONO-4578
Prostaglandin receptor (EP4) antagonist
ONO-4685
PD-1 x CD3 bispecific antibody
ONO-7018
MALT1 inhibitor
ONO-7475 (tamnorzatinib)
Axl/Mer inhibitor
ONO-7914
STING agonist
ONO-8250
iPSC-derived HER2 CAR T-cell therapy
ONO-4685
PD-1 x CD3 bispecific antibody
ONO-4059 (tirabrutinib)
BTK inhibitor
ONO-1110
Endocannabinoid regulation
ONO-2020
Epigenetic regulation
ONO-2808
S1P5 receptor agonist
ONO-2910
Enhancement of Schwann cell differentiation
Our Global Pipeline
ONO is investigating additional therapeutics across our four focus areas globally.
![Our Global Pipeline](/sites/default/files/2023-11/Pipeline_Global.png)
![Contact Us](/sites/default/files/2023-11/AboutUs_BottomLinks_Contact.png)
![Work@ONO](/sites/default/files/2023-11/OurScience_BottomLinks_WorkAtONO.png)